To report the FDA approval of nipocalimab-aahu (IMAAVY) for the treatment of warm autoimmune hemolytic anemia (wAIHA).
Approach:
Approval Details: Nipocalimab-aahu is approved for adults and pediatric patients aged 12 years and older with wAIHA who are currently or were previously treated with corticosteroids.
Mechanism of Action: Nipocalimab binds to and blocks the neonatal Fc receptor, reducing circulating immunoglobulin G antibodies while preserving B-cell function.
Study Design: The approval was based on the phase 2/3 ENERGY trial, a multicenter, randomized, double-blind, placebo-controlled study involving 115 adults with wAIHA.
Endpoints: The primary endpoint was durable hemoglobin response, defined as a hemoglobin concentration of at least 10 g/dL and an increase of at least 2 g/dL from baseline for at least 28 days.
Key Findings:
Approximately 3 times as many participants receiving nipocalimab achieved a durable hemoglobin response compared to those receiving placebo by week 24.
Participants receiving nipocalimab had a mean hemoglobin increase of 1 g/dL at week 1.
At week 24, the mean change in fatigue score was 3.5 points higher with nipocalimab compared to placebo.
Interpretation:
The findings were characterized as descriptive under the prespecified statistical analysis plan.
Limitations:
The study involved a limited sample size of 115 participants.
The findings are based on a specific patient population with wAIHA.
Conclusion:
Nipocalimab is the first therapy approved specifically for wAIHA, demonstrating efficacy in increasing hemoglobin levels and reducing fatigue.
Investigators linked distinct odor patterns to life stage, sex, and skin microbes, while limited longitudinal evidence leaves their clinical utility uncertain.
